Galena Biopharma (SLS)
(Delayed Data from NSDQ)
$1.26 USD
+0.02 (1.61%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $1.27 +0.01 (0.79%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.26 USD
+0.02 (1.61%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $1.27 +0.01 (0.79%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth A Momentum D VGM
Zacks News
Galena Biopharma (SLS) Upgraded to Buy: Here's Why
by Zacks Equity Research
Galena Biopharma (SLS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Galena Biopharma (SLS) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Galena Biopharma (SLS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
SELLAS (SLS) Rises on FDA Fast Track Tag to Leukemia Candidate
by Zacks Equity Research
The FDA bestows a Fast Track Designation to SELLAS' (SLS) pipeline candidate, SLS009, for the treatment of relapsed/refractory acute myeloid leukemia. Stock gains.
Galena Biopharma, Inc. (SLS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Galena Biopharma, Inc. (SLS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.